Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update
May 17, 2022, 07:30 ET Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half Calendar 2022 Vyleesi® – Gross product sales increased 67%, net product revenue increased 200% and prescriptions dispensed increased 20%, over the prior quarter Closed on a …